# Gypenoside (Gynostemma pentaphyllum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/gypenoside-gynostemma-pentaphyllum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Gynostemma pentaphyllum saponins, Jiaogulan saponins, dammarane-type triterpene saponins, GP saponins, Gyps

## Overview

Gypenosides are a family of over 100 dammarane-type triterpene saponins that exert antioxidant, [anti-inflammatory](/ingredients/condition/inflammation), and anti-cancer effects by suppressing NF-κB signaling, inhibiting the PI3K/AKT/mTOR pathway, and modulating [reactive oxygen species](/ingredients/condition/antioxidant) and inflammatory cytokines including IL-1β, IL-6, and TNF-α. Preclinical models demonstrate that high-content monomers gypenoside L and gypenoside LI inhibit A549 lung cancer cell proliferation with IC50 values of 29.38 ± 2.52 μM and 21.36 ± 0.78 μM, respectively, while gypenoside XLIX at 20–30 mg/kg shows cardioprotective and anti-atherosclerotic activity in murine models.

## Health Benefits

- **Antioxidant Defense**: Gypenoside XVII, the most prevalent monomer bearing a C-20β-OH structure, reduces malondialdehyde (MDA) and [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) while simultaneously elevating superoxide dismutase (SOD), catalytic antioxidant (CAT), glutathione (GSH), and total antioxidant capacity (T-AOC), providing broad-spectrum protection against oxidative cellular damage.
- **Anti-Inflammatory Activity**: Gypenosides suppress the NLRP3 inflammasome pathway, inhibit caspase-1 and gasdermin D (GSDMD) cleavage, and reduce NF-κB-driven transcription of IL-1β, IL-6, and TNF-α, effects documented in sepsis-induced acute stress injury, atherosclerosis, and renal ischemia-reperfusion preclinical models.
- **Anti-Cancer Potential**: In gastric cancer cell lines HGC-27 and SGC-7901, total gypenosides at 50–100 μg/mL reduce cell survival below 50% by inhibiting the PI3K/AKT/mTOR pathway, inducing S, G0-G1, and G2-M phase arrest, triggering cytochrome c release, and activating caspase-dependent apoptosis with concurrent downregulation of CDK2, CDK4, CDK1, Bcl-2, MMP2, and MMP9.
- **[Cardiovascular](/ingredients/condition/heart-health) and Antihypertensive Support**: Gypenoside XLIX at 20–30 mg/kg in murine atherosclerosis models reduces lipid plaque formation and vascular inflammation through antioxidant and NF-κB-suppressive mechanisms, supporting its traditional use as an antihypertensive agent in Jiaogulan-based herbal formulas.
- **[Hepatoprotective](/ingredients/condition/detox) Effects**: In liver fibrosis models, gypenosides at 3–30 mg/kg lower serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), hydroxyproline (HYP), TNF-α, and IL-1β, indicating protection against hepatocellular damage and fibrotic remodeling likely mediated through antioxidant and anti-[inflammatory pathway](/ingredients/condition/inflammation)s.
- **[Neuroprotective](/ingredients/condition/cognitive) and Microglial Modulation**: Gypenosides alleviate LPS-induced neuroinflammation in microglia by modulating complement component C3, postsynaptic density protein 95 (PSD95), vesicular glutamate transporter 1 (vGluT1), and ionized calcium-binding adaptor molecule 1 (Iba1), suggesting a role in protecting synaptic integrity during neuroinflammatory insults.
- **Metabolic Regulation**: Traditional and emerging preclinical data attribute hypoglycemic activity to gypenosides, with mechanisms thought to involve improved [insulin sensitivity](/ingredients/condition/weight-management) and reduced inflammatory interference with glucose metabolism, although specific molecular targets for this application remain under active investigation.

## Mechanism of Action

Gypenosides primarily suppress oxidative stress by scavenging [reactive oxygen species](/ingredients/condition/antioxidant) and upregulating endogenous antioxidant enzymes—SOD, CAT, GSH-Px, and GSH—while reducing lipid peroxidation end-products such as MDA, effects linked especially to gypenoside XVII's C-20β-OH configuration. Anti-inflammatory activity proceeds through inhibition of NF-κB nuclear translocation, which attenuates transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s (IL-1β, IL-6, TNF-α) and suppresses NLRP3 inflammasome assembly, caspase-1 activation, and gasdermin D-mediated pyroptosis. In oncological contexts, molecular docking studies indicate strong binding affinity of gypenosides to PI3K, AKT, and mTOR kinase domains, resulting in downstream inhibition of cell-cycle regulatory proteins CDK1/2/4, anti-apoptotic protein Bcl-2, and matrix metalloproteinases MMP2 and MMP9, culminating in mitochondria-dependent apoptosis via cytochrome c release and caspase cascade activation. Additional mechanistic targets include C3 complement modulation and synaptic protein regulation (PSD95, vGluT1, Iba1) in microglial inflammation, and ALT/AST pathway normalization in hepatic models, underscoring the compound class's pleiotropic, multi-target pharmacological profile.

## Clinical Summary

No published human clinical trials with defined sample sizes, randomized controls, or effect-size data specific to isolated gypenosides have been identified; available human-relevant evidence is limited to the traditional use of Gynostemma pentaphyllum tea and standardized whole-plant extracts in Asian ethnomedicine. Preclinical models have quantified outcomes such as cell viability reduction below 50% at 50–100 μg/mL in gastric cancer lines, IC50 values in the 21–30 μM range for lung cancer monomers, and dose-dependent reductions in [inflammatory](/ingredients/condition/inflammation) biomarkers (TNF-α, IL-1β, ALT, AST) in rodents at 3–30 mg/kg. These findings demonstrate consistent mechanistic signals across independent research groups, but the absence of pharmacokinetic data, human bioavailability studies, and controlled clinical outcomes means that effect sizes in humans remain entirely unknown. Confidence in clinical recommendations is therefore low, and gypenosides should currently be regarded as a research-stage ingredient warranting rigorous clinical investigation.

## Nutritional Profile

Gypenosides as isolated compounds are triterpene saponins and contribute negligible macronutrient content (carbohydrates, fats, proteins) in supplemental doses. The parent plant Gynostemma pentaphyllum leaves contain polysaccharides, flavonoids (quercetin, rutin), chlorophyll, and minor amounts of vitamins and minerals, but these are largely absent in purified gypenoside extracts. The primary phytochemical constituents of standardized extracts are the saponin complex totaling up to 76.809 mg/g dry weight under optimized conditions, dominated by gypenoside XVII with a C-20β-OH stereochemical configuration conferring strong [antioxidant activity](/ingredients/condition/antioxidant), alongside structural analogs of ginsenosides Rb1, Rb3, Rd, and F2. Bioavailability of individual gypenoside monomers following oral ingestion has not been characterized in human pharmacokinetic studies; the large molecular weight and amphiphilic nature of saponins generally predict moderate intestinal absorption, possible [gut microbiome](/ingredients/condition/gut-health)-mediated deglycosylation to more bioavailable aglycone forms (dammarenediols), and hepatic first-pass [metabolism](/ingredients/condition/weight-management), though these processes remain unquantified for this compound class.

## Dosage & Preparation

- **Whole-plant herbal tea (Jiaogulan)**: Traditional preparation involves steeping 3–6 g of dried Gynostemma pentaphyllum leaves in hot water (70–80°C) for 5–10 minutes; no standardized gypenoside content is guaranteed with this method.
- **Standardized leaf extract capsules/tablets**: Commercial extracts are typically standardized to 20–98% total gypenosides by UV-spectrophotometric or HPLC methods; common supplement doses range from 150–450 mg of standardized extract per day, though human clinical dose-finding trials are absent.
- **Preclinical animal dosing reference**: Murine studies use gypenoside XLIX at 20–30 mg/kg body weight and total gypenoside preparations at 3–30 mg/kg; direct extrapolation to human equivalent doses has not been validated.
- **Cell culture reference concentrations**: In vitro anti-cancer work uses 25–200 μg/mL (GP-17) and 30–150 μg/mL (total gypenosides), concentrations that are not directly applicable to oral supplementation.
- **Elicitor-optimized extract**: Suspension cell culture treated with 100 μM salicylic acid yields up to 76.809 mg total gypenosides per gram dry weight; this production method is research-stage and not yet standard in commercial manufacturing.
- **Timing**: No human pharmacokinetic data exist to inform optimal timing; traditional use suggests consumption with or between meals as herbal tea.

## Safety & Drug Interactions

Gypenosides exhibit concentration-dependent cytotoxicity in vitro, with gypenoside XLIX reducing RAW264.7 macrophage viability at concentrations of 10–80 μM while showing no significant effect at 5 μM, suggesting a therapeutic window that has not yet been defined in humans. Isolated high-content monomers gypenoside L and LI suppress cancer cell survival below 50% at 50–100 μg/mL, raising theoretical concerns about selectivity for normal versus malignant cells at higher doses, though no systematic human toxicology studies have been conducted. No specific drug interaction data are available for gypenosides; however, given their anti-platelet, antihypertensive, and hypoglycemic preclinical profiles, caution is advisable when co-administering with antihypertensive agents, anticoagulants (e.g., warfarin, heparin), antiplatelet drugs, or oral hypoglycemics, as additive effects are plausible. Pregnancy and lactation safety has not been evaluated in controlled studies; use during these periods should be avoided pending safety data, and individuals with autoimmune conditions or scheduled for surgery should consult a qualified healthcare provider before use.

## Scientific Research

The current evidence base for gypenosides is composed almost entirely of in vitro cell culture experiments and in vivo rodent models, with no well-powered, randomized controlled human clinical trials identified in the published literature as of mid-2025. Preclinical anti-cancer studies use cancer cell lines such as A549 (lung), HGC-27, and SGC-7901 (gastric) with quantified IC50 values (gypenoside L: 29.38 ± 2.52 μM; gypenoside LI: 21.36 ± 0.78 μM), while [cardiovascular](/ingredients/condition/heart-health) and [anti-inflammatory](/ingredients/condition/inflammation) work relies on murine atherosclerosis, sepsis, and renal ischemia-reperfusion models at doses of 20–30 mg/kg. [Hepatoprotective](/ingredients/condition/detox) findings (ALT, AST, HYP reductions) and microglial anti-inflammatory data (C3, PSD95, vGluT1, Iba1 modulation) are likewise derived from animal and macrophage (RAW264.7, THP-1) model systems, providing mechanistic plausibility but limited direct translation to human therapeutic dosing. Overall, the scientific evidence is promising but preliminary; translational human studies are needed before efficacy or safety claims can be made with clinical confidence.

## Historical & Cultural Context

Gynostemma pentaphyllum has been used in traditional Chinese and Vietnamese medicine for centuries, documented in Chinese herbals as 'Jiaogulan' (literally 'twisting-vine orchid') and colloquially nicknamed the 'herb of immortality' due to its association with [longevity](/ingredients/condition/longevity) in populations of southern China who consumed it regularly as a daily tea. Historical texts and ethnobotanical records describe its use in treating atherosclerosis, hyperlipidemia, hypertension, [inflammation](/ingredients/condition/inflammation), and fatigue, with the saponin-rich leaf fraction considered the primary pharmacologically active component. In Japan, the plant is known as 'amachazuru,' and rural mountain communities historically prepared it as a cold-water or hot infusion consumed throughout the day as a restorative tonic. Formal isolation and structural characterization of gypenosides began in the 1970s–1980s by Japanese and Chinese researchers, who recognized the structural homology between several gypenoside monomers (e.g., gypenosides III, IV, VIII, XII) and well-studied ginsenosides from Panax ginseng, triggering comparative pharmacological interest that continues today.

## Synergistic Combinations

Gypenosides share structural and mechanistic homology with Panax ginseng ginsenosides (particularly Rb1, Rb3, Rd, F2), and co-administration of Jiaogulan extract with ginseng preparations has been explored in traditional Asian formulas to achieve complementary [adaptogen](/ingredients/condition/stress)ic, antioxidant, and metabolic effects via overlapping but non-identical saponin receptor interactions. The [antioxidant activity](/ingredients/condition/antioxidant) of gypenoside XVII may be potentiated by co-supplementation with vitamin C or quercetin, as these compounds act on complementary ROS-quenching pathways (enzymatic via SOD/CAT upregulation versus direct radical scavenging), though this synergy has not been formally tested in clinical settings. In [anti-inflammatory](/ingredients/condition/inflammation) contexts, preclinical logic supports combining gypenosides with omega-3 fatty acids (EPA/DHA) to achieve dual NF-κB suppression and COX/LOX pathway modulation, representing a mechanistically rational but empirically unvalidated stack.

## Frequently Asked Questions

### What are gypenosides and where do they come from?

Gypenosides are a family of over 100 dammarane-type triterpene saponins extracted primarily from the leaves and stems of Gynostemma pentaphyllum (Jiaogulan), a climbing plant native to southern China, Japan, Korea, and Southeast Asia. They are structurally related to ginsenosides from Panax ginseng, with several monomers—including gypenosides III, IV, VIII, and XII—sharing near-identical chemical structures with ginsenosides Rb1, Rb3, Rd, and F2. Gypenoside XVII is the most prevalent monomer identified and is associated with the compound class's strongest antioxidant activity.

### What do gypenosides do in the body?

Gypenosides exert antioxidant effects by upregulating SOD, CAT, GSH, and T-AOC while reducing ROS and MDA, and they suppress inflammation by inhibiting NF-κB signaling and the NLRP3 inflammasome, lowering cytokines IL-1β, IL-6, and TNF-α. In cancer research contexts, they inhibit the PI3K/AKT/mTOR pathway, induce cell cycle arrest and apoptosis in gastric and lung cancer cell lines, and downregulate survival proteins including Bcl-2 and CDK1/2/4. Additional preclinical activities include hepatoprotection, microglial anti-inflammatory modulation, and cardiovascular support in atherosclerosis models.

### Are there human clinical trials on gypenosides?

As of mid-2025, no well-controlled, randomized human clinical trials with defined sample sizes and effect-size data have been published specifically for isolated gypenosides. The available evidence is derived from in vitro cell line studies and in vivo rodent models, including murine atherosclerosis, sepsis, liver fibrosis, and cancer cell experiments. While the traditional use of Gynostemma pentaphyllum as a whole-plant preparation has centuries of ethnomedicinal documentation, this does not substitute for controlled clinical evidence on purified gypenoside extracts.

### What is the recommended dosage for gypenosides?

No standardized human clinical dosage has been established for gypenosides because pharmacokinetic and dose-finding trials in humans are lacking. Commercial standardized Gynostemma pentaphyllum extracts are commonly marketed at 150–450 mg per day of material standardized to 20–98% total gypenosides, but these ranges are not derived from clinical trial evidence. Preclinical animal studies used 3–30 mg/kg for hepatoprotective effects and 20–30 mg/kg for cardiovascular effects (gypenoside XLIX), doses that cannot be directly extrapolated to human equivalent amounts without allometric validation.

### Are gypenosides safe, and do they interact with medications?

Gypenosides show concentration-dependent cytotoxicity in cell studies, with no significant toxicity observed at 5 μM in macrophage cultures but reduced cell viability at 10–80 μM, indicating a dose threshold of concern that has not been translated into human safety data. Given their antihypertensive, hypoglycemic, and potential anticoagulant preclinical activities, they may theoretically interact with blood pressure medications, blood sugar-lowering drugs, and anticoagulants such as warfarin, increasing the risk of excessive pharmacological effects when combined. Human toxicology, teratogenicity, and interaction studies are absent, so pregnant or lactating individuals and those on chronic medications should seek medical guidance before use.

### How does gypenoside XVII specifically differ from other gypenosides in terms of antioxidant activity?

Gypenoside XVII is the most abundant gypenoside monomer and is distinguished by its C-20β-OH chemical structure, which makes it particularly effective at reducing oxidative stress markers like malondialdehyde and reactive oxygen species. Unlike other gypenosides, gypenoside XVII uniquely elevates multiple antioxidant enzymes simultaneously—superoxide dismutase, catalase, and glutathione levels—providing broader cellular protection. This makes gypenoside XVII the primary bioactive compound responsible for gynostemma's antioxidant reputation in scientific literature.

### What is the bioavailability difference between whole gynostemma leaf extract and isolated gypenosides?

Whole gynostemma pentaphyllum leaf extracts contain gypenosides alongside other bioactive compounds and polysaccharides that may enhance absorption through synergistic mechanisms, whereas isolated gypenoside extracts provide standardized concentrations of individual compounds. Standardized gypenoside extracts typically offer higher concentration of active ingredients per dose but may have different absorption kinetics than whole-leaf preparations. The choice between formats depends on whether synergistic multi-compound benefits or precise dosing of gypenosides is prioritized.

### Which populations would benefit most from gypenoside supplementation based on its antioxidant mechanism?

Individuals with elevated oxidative stress—including those with chronic inflammatory conditions, metabolic disorders, or exposure to environmental toxins—may benefit most from gypenosides' ability to reduce ROS and malondialdehyde while boosting endogenous antioxidant enzymes. Athletes and active individuals experiencing exercise-induced oxidative damage are also logical candidates, as gypenosides address multiple pathways of cellular oxidative damage simultaneously. Older adults may particularly benefit since antioxidant enzyme activity naturally declines with age and gypenosides specifically elevate SOD, CAT, and GSH levels.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*